Top 10 at 11: Dicker Data founder sells $90.47 million worth of stock following divorce settlement

Stockhead’s Top 10 at 11, published each trading day, highlights the best (and worst) performing ASX stocks in morning trade using live data.

It’s a short, sharp update to help frame the trading day by showing the biggest movers in percentage terms.

The market opens at 10am (eastern time) and the data is taken at 10:15am, once every ASX stock has started trading.

WINNERS

Stocks highlighted in yellow have made market-moving announcements (click headings to sort).

Code	Description	Last	%	Volume	MktCap
AT1	Atomo Diagnostics	0.052	93%	8,004,823	$17,258,462
MCT	Metalicity Limited	0.0025	25%	3,721,236	$8,970,108
NVQ	Noviqtech Limited	0.005	25%	1,210,000	$5,237,781
1AD	Adalta Limited	0.03	20%	12,475,013	$13,145,102
88E	88 Energy Ltd	0.006	20%	24,865,026	$125,620,313
AL8	Alderan Resource Ltd	0.006	20%	4,000,000	$5,534,307
OAU	Ora Gold Limited	0.006	20%	100,000	$28,700,004
RNX	Renegade Exploration	0.007	17%	476,928	$6,010,343
ALM	Alma Metals Ltd	0.008	14%	6,250	$7,798,006
POS	Poseidon Nick Ltd	0.008	14%	740,223	$25,994,743

Atomo Diagnostics (ASX:AT1) has announced it’s secured ~$970,000 worth of orders from Viatris Healthcare Pty Ltd for its HIV Self-Tests, manufactured by Atomo under the Mylan brand for supply to a number of Low- and Middle-Income Countries (LMICs) with manufacture during H2 FY24.

Metalicity (ASX:MCT) says drilling approvals at its 80% owned Yundamindra Gold Project (20% owned by JV partner Nex Metals Exploration (ASX:NME) have been lodged for the first drilling program in over a decade. MCT says following favourable Wardens Court decisions regarding the Yundamindra tenements the company has been undertaking extensive internal and external review of all historical data and activities at the highly prospective gold project.

AdAlta (ASX:1AD) says key results from its Phase I extension study of lead asset AD-214 have achieved the critical milestones including positively answered key partnering discussion questions from pharma companies, while establishing the safety and tolerability of the planned Phase II dose.

AD-214 is being developed for fibrotic diseases including the debilitating and fatal disease, Idiopathic Pulmonary Fibrosis (IPF) and is now ready to progress to Phase II clinical studies.

LOSERS

Stocks highlighted in yellow have made market-moving announcements (click headings to sort).

Code	Company	Price	%	Volume	Market Cap
ASQ	Australian Silica	0.016	-65%	158,087	$12,965,577
CTT	Cettire	3.5	-25%	4,067,078	$1,776,570,105
TSL	Titanium Sands Ltd	0.007	-22%	32,524	$17,943,572
EDE	Eden Inv Ltd	0.002	-20%	380,375	$9,195,678
GCM	Green Critical Min	0.005	-17%	45,186	$6,819,510
REY	REY Resources Ltd	0.085	-15%	900	$21,168,754
ZNO	Zoono Group Ltd	0.035	-13%	3,000	$8,547,096
DDR	Dicker Data Limited	10.63	-12%	18,751,041	$2,173,303,320
SGA	Sarytogan	0.2	-11%	129,141	$17,313,729
ADG	Adelong Gold Limited	0.004	-11%	4,350,500	$3,230,950

Dicker Data (ASX:DDR) has announced founder, chairman and CEO has David Dicker has sold down ~8.3 million shares representing ~10.2% of the company’s issued capital due to a recent divorce settlement and restructuring of his portfolio.

The sale was undertaken at a price of $10.90 per share by way of an underwritten block trade equating to ~$90.47 million.

DDR says its free float is expected to increase from ~36% to 46% and Dicker has entered into a 6-month escrow on his remaining shareholding.

Biotech developing antimicrobial solutions Zoono Group (ASX:ZNO) has entered into an exclusive agency agreement with OSY Group Limited (OSY) to promote the sale of Zoono products for he food supply chain sector. ZNO says based in Manchester, England OSY is a leading-edge provider of sustainable technologies in the hygiene technology sector.